BPC-157 · research summary

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

Frontiers in aging · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Comprehensive narrative review of peptide therapeutics in gerontological medicine
“A comprehensive narrative review was conducted through systematic searches of PubMed, Scopus, and regulatory databases (FDA, WADA) from inception through January 2026.”

Subjects

Nine therapeutic peptides including tirzepatide, epitalon, GHK-Cu, BPC-157, TB-500, Semax, CJC-1295, ipamorelin, and bremelanotide
“Nine peptides were identified spanning diverse aging interventions: metabolic restoration (tirzepatide), telomere biology (epitalon), dermal regeneration (GHK-Cu), tissue repair (BPC-157, TB-500), neuroprotection (Semax), growth hormone modulation (CJC-1295, ipamorelin), and sexual function (bremelanotide).”

Sample size

20 primary sources selected for evaluation
“A total of 20 primary sources were selected based on relevance, methodological quality, and contribution to understanding peptide mechanisms and clinical outcomes in aging populations.”

Duration

Searches conducted from inception through January 2026
“A comprehensive narrative review was conducted through systematic searches of PubMed, Scopus, and regulatory databases (FDA, WADA) from inception through January 2026.”

Reported findings

FDA-approved agents demonstrated robust safety profiles from large-scale trials, while non-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data.
“FDA-approved agents demonstrated robust safety profiles from large-scale trials. Non-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation.”
Investigational peptides require rigorous validation through well-designed clinical trials to establish safety and efficacy for healthspan extension.
“While FDA-approved agents demonstrate clinical potential, investigational peptides require rigorous validation through well-designed clinical trials to establish safety and efficacy for healthspan extension.”

Source: PubMed 42021992 · DOI 10.3389/fragi.2026.1790247 · all study summaries

Subjects

Nine therapeutic peptides including tirzepatide, epitalon, GHK-Cu, BPC-157, TB-500, Semax, CJC-1295, ipamorelin, and bremelanotide

“Nine peptides were identified spanning diverse aging interventions: metabolic restoration (tirzepatide), telomere biology (epitalon), dermal regeneration (GHK-Cu), tissue repair (BPC-157, TB-500), neuroprotection (Semax), growth hormone modulation (CJC-1295, ipamorelin), and sexual function (bremelanotide).”

Reported findings

FDA-approved agents demonstrated robust safety profiles from large-scale trials, while non-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data.

“FDA-approved agents demonstrated robust safety profiles from large-scale trials. Non-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation.”

Investigational peptides require rigorous validation through well-designed clinical trials to establish safety and efficacy for healthspan extension.

“While FDA-approved agents demonstrate clinical potential, investigational peptides require rigorous validation through well-designed clinical trials to establish safety and efficacy for healthspan extension.”